Shares of USANA Health Sciences (NASDAQ:USNA) have been given an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a 12 month consensus price objective of $137.67 for the company and are anticipating that the company will post $1.81 earnings per share for the current quarter, according to Zacks. Zacks has also assigned USANA Health Sciences an industry rank of 68 out of 265 based on the ratings given to related companies.
Several brokerages have commented on USNA. DA Davidson started coverage on USANA Health Sciences in a research note on Friday, June 26th. They issued a “buy” rating and a $165.00 price target on the stock. Canaccord Genuity reissued a “hold” rating and issued a $136.00 price objective on shares of USANA Health Sciences in a research note on Wednesday, August 5th. Zacks upgraded USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $167.00 target price for the company in a research report on Tuesday, August 25th. Finally, Pivotal Research upgraded USANA Health Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $135.00 to $200.00 in a report on Wednesday, August 5th.
Be the first to comment on "(NASDAQ:USNA) Upgraded to BUY"